COMMUNIQUÉS West-GlobeNewswire

CorVel Appoints Sarah Scott CEO and President; Michael G. Combs to Transition to Executive Chair
01/06/2026
FORT WORTH, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- CorVel today announced that Sarah Scott will be appointed CEO and President, effective July 1, 2026, succeeding Michael G. Combs, who will transition to the role of [...]
Teva to Present at the Goldman Sachs Global Healthcare Conference
01/06/2026
PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in a [...]
Praxis Precision Medicines Provides Vormatrigine Program Update
01/06/2026
POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second half of the study [...]
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
01/06/2026
PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/06/2026
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
01/06/2026
Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Minerva [...]
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
01/06/2026
Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). SAN DIEGO, June 01, 2026 (GLOBE [...]
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/06/2026
NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
01/06/2026
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk profile of pociredir in [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/06/2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly- [...]
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
01/06/2026
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis At Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the [...]
Abivax annonce des résultats majeurs de l’essai de maintenance de phase 3 ABTECT évaluant l’obéfazimod dans le traitement de la rectocolite hémorragique active modérée à sévère
01/06/2026
Abivax annonce des résultats majeurs de l’essai de maintenance de phase 3 ABTECT évaluant l’obéfazimod dans le traitement de la rectocolite hémorragique active modérée à sévère À la semaine 44, les deux doses d’ [...]
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
01/06/2026
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced [...]
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
01/06/2026
LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
01/06/2026
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock [...]
Fourfront Contributor launches ‘Return on Response’ campaign to highlight value of behavioral health and law enforcement crisis response partnerships
01/06/2026
Coalition warns proposed federal legislation may force more individuals to seek crisis care, reinforcing the need for community behavioral health co-response models that save time, money and lives EVERETT, SEATTLE, [...]
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
01/06/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following [...]
IBA – ACQUISITION OF OWN SHARES
01/06/2026
Louvain-la-Neuve, Belgium, June 1 st , 2026 – 9 PM CEST – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
IBA – ACQUISITION D’ACTIONS PROPRES
01/06/2026
Louvain-la-Neuve, Belgique, 1 er juin 2026 – 21h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]

Pages